Concepts (128)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Myositis | 11 | 2024 | 266 | 4.550 |
Why?
|
| Lung Diseases, Interstitial | 19 | 2024 | 865 | 4.020 |
Why?
|
| Idiopathic Pulmonary Fibrosis | 4 | 2024 | 484 | 1.090 |
Why?
|
| Rheumatology | 5 | 2024 | 597 | 0.990 |
Why?
|
| Autoimmune Diseases | 6 | 2024 | 2193 | 0.830 |
Why?
|
| Dyspnea | 2 | 2019 | 1308 | 0.790 |
Why?
|
| Amino Acyl-tRNA Synthetases | 1 | 2021 | 90 | 0.740 |
Why?
|
| Connective Tissue Diseases | 2 | 2021 | 275 | 0.710 |
Why?
|
| Furosemide | 1 | 2019 | 161 | 0.660 |
Why?
|
| Sodium Potassium Chloride Symporter Inhibitors | 1 | 2019 | 136 | 0.640 |
Why?
|
| Rheumatic Diseases | 4 | 2024 | 622 | 0.590 |
Why?
|
| Lymphoma, B-Cell, Marginal Zone | 1 | 2018 | 179 | 0.570 |
Why?
|
| Strongylida Infections | 1 | 2017 | 47 | 0.570 |
Why?
|
| Immunoglobulins, Intravenous | 2 | 2019 | 651 | 0.520 |
Why?
|
| Autoantibodies | 4 | 2024 | 2044 | 0.460 |
Why?
|
| Polymyositis | 1 | 2014 | 75 | 0.460 |
Why?
|
| Lung | 9 | 2024 | 9918 | 0.440 |
Why?
|
| Thermogenesis | 1 | 2017 | 446 | 0.420 |
Why?
|
| Dermatomyositis | 1 | 2014 | 248 | 0.370 |
Why?
|
| Critical Illness | 1 | 2024 | 2693 | 0.370 |
Why?
|
| Lung Diseases | 1 | 2019 | 1902 | 0.340 |
Why?
|
| Hemorrhage | 1 | 2019 | 3521 | 0.300 |
Why?
|
| Thalidomide | 1 | 2012 | 882 | 0.290 |
Why?
|
| Pulmonary Fibrosis | 3 | 2018 | 529 | 0.280 |
Why?
|
| Adrenal Cortex Hormones | 2 | 2019 | 1867 | 0.270 |
Why?
|
| Immunosuppressive Agents | 3 | 2019 | 4057 | 0.250 |
Why?
|
| Antirheumatic Agents | 1 | 2014 | 1351 | 0.230 |
Why?
|
| Glucocorticoids | 3 | 2024 | 2119 | 0.210 |
Why?
|
| Lung Neoplasms | 4 | 2022 | 13218 | 0.210 |
Why?
|
| Macrophages | 2 | 2017 | 5664 | 0.210 |
Why?
|
| Disease Progression | 7 | 2024 | 13317 | 0.210 |
Why?
|
| Respiratory Function Tests | 3 | 2024 | 1667 | 0.200 |
Why?
|
| Pulmonary Stretch Receptors | 1 | 2019 | 12 | 0.180 |
Why?
|
| Arthritis, Rheumatoid | 2 | 2024 | 3734 | 0.180 |
Why?
|
| Bronchoscopy | 1 | 2024 | 887 | 0.160 |
Why?
|
| Infarction | 1 | 2019 | 247 | 0.160 |
Why?
|
| Immunologic Factors | 2 | 2019 | 1567 | 0.150 |
Why?
|
| Helminthiasis, Animal | 1 | 2017 | 4 | 0.150 |
Why?
|
| Fibrosis | 2 | 2022 | 2012 | 0.150 |
Why?
|
| Nippostrongylus | 1 | 2017 | 21 | 0.150 |
Why?
|
| Aerosols | 1 | 2019 | 629 | 0.140 |
Why?
|
| Pulmonary Alveoli | 1 | 2019 | 665 | 0.140 |
Why?
|
| Administration, Inhalation | 1 | 2019 | 1140 | 0.140 |
Why?
|
| Humans | 26 | 2024 | 746630 | 0.130 |
Why?
|
| Off-Label Use | 1 | 2016 | 177 | 0.120 |
Why?
|
| Cross-Over Studies | 1 | 2019 | 2015 | 0.110 |
Why?
|
| Gene Knockout Techniques | 1 | 2017 | 788 | 0.110 |
Why?
|
| Pyridones | 1 | 2018 | 750 | 0.110 |
Why?
|
| Radiography, Thoracic | 1 | 2019 | 1275 | 0.110 |
Why?
|
| Thromboembolism | 1 | 2019 | 1003 | 0.110 |
Why?
|
| Cyclosporine | 1 | 2014 | 751 | 0.100 |
Why?
|
| Exercise Test | 1 | 2019 | 2081 | 0.100 |
Why?
|
| Tomography, X-Ray Computed | 5 | 2024 | 20143 | 0.100 |
Why?
|
| Tomography, Optical Coherence | 1 | 2024 | 2805 | 0.100 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2014 | 693 | 0.100 |
Why?
|
| Tacrolimus | 1 | 2014 | 718 | 0.090 |
Why?
|
| Indoles | 1 | 2018 | 1806 | 0.090 |
Why?
|
| Scleroderma, Systemic | 2 | 2024 | 340 | 0.090 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 2021 | 1396 | 0.090 |
Why?
|
| Retrospective Studies | 4 | 2023 | 78313 | 0.090 |
Why?
|
| Hypertension, Pulmonary | 1 | 2020 | 1542 | 0.080 |
Why?
|
| Male | 11 | 2024 | 351420 | 0.080 |
Why?
|
| Middle Aged | 8 | 2024 | 214618 | 0.070 |
Why?
|
| Docosahexaenoic Acids | 1 | 2014 | 892 | 0.070 |
Why?
|
| Neutrophils | 1 | 2019 | 3709 | 0.070 |
Why?
|
| Prevalence | 1 | 2024 | 15312 | 0.070 |
Why?
|
| Pulmonary Embolism | 1 | 2019 | 2499 | 0.070 |
Why?
|
| Pneumonia | 1 | 2018 | 2116 | 0.070 |
Why?
|
| Prognosis | 3 | 2020 | 29079 | 0.070 |
Why?
|
| Phenotype | 2 | 2021 | 16261 | 0.070 |
Why?
|
| Air Pollution | 1 | 2019 | 2288 | 0.060 |
Why?
|
| Double-Blind Method | 1 | 2019 | 12227 | 0.060 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2019 | 3148 | 0.060 |
Why?
|
| Aged | 6 | 2024 | 164383 | 0.060 |
Why?
|
| Chronic Disease | 1 | 2019 | 9124 | 0.060 |
Why?
|
| Environmental Exposure | 1 | 2019 | 4315 | 0.060 |
Why?
|
| Mixed Connective Tissue Disease | 1 | 2024 | 32 | 0.060 |
Why?
|
| Immunity, Innate | 1 | 2017 | 3025 | 0.060 |
Why?
|
| Combined Modality Therapy | 1 | 2016 | 8521 | 0.060 |
Why?
|
| Diagnosis, Differential | 1 | 2019 | 12840 | 0.060 |
Why?
|
| Drug Therapy, Combination | 1 | 2014 | 6463 | 0.060 |
Why?
|
| Mice, Inbred C57BL | 3 | 2017 | 21600 | 0.060 |
Why?
|
| Female | 9 | 2024 | 382450 | 0.050 |
Why?
|
| Sjogren's Syndrome | 1 | 2024 | 234 | 0.050 |
Why?
|
| Societies, Medical | 2 | 2024 | 3790 | 0.050 |
Why?
|
| Bleomycin | 2 | 2014 | 504 | 0.050 |
Why?
|
| Treatment Outcome | 4 | 2019 | 63732 | 0.050 |
Why?
|
| Cells, Cultured | 1 | 2017 | 18905 | 0.050 |
Why?
|
| Asthma | 1 | 2019 | 6139 | 0.050 |
Why?
|
| Adenocarcinoma | 1 | 2018 | 6300 | 0.040 |
Why?
|
| Vaccination | 1 | 2012 | 3283 | 0.040 |
Why?
|
| Cell Differentiation | 1 | 2017 | 11384 | 0.040 |
Why?
|
| Pulmonary Diffusing Capacity | 1 | 2019 | 95 | 0.040 |
Why?
|
| Mass Screening | 2 | 2024 | 5334 | 0.040 |
Why?
|
| Prospective Studies | 1 | 2023 | 53253 | 0.040 |
Why?
|
| Occupations | 1 | 2020 | 504 | 0.040 |
Why?
|
| Disease Models, Animal | 1 | 2017 | 17869 | 0.040 |
Why?
|
| Risk Factors | 4 | 2020 | 72447 | 0.040 |
Why?
|
| Vital Capacity | 1 | 2019 | 953 | 0.030 |
Why?
|
| Ozone | 1 | 2019 | 466 | 0.030 |
Why?
|
| Carbon Monoxide | 1 | 2019 | 540 | 0.030 |
Why?
|
| Carbon | 1 | 2019 | 673 | 0.030 |
Why?
|
| Aged, 80 and over | 1 | 2019 | 57586 | 0.030 |
Why?
|
| Mice | 3 | 2017 | 80251 | 0.030 |
Why?
|
| Prednisone | 1 | 2019 | 1559 | 0.030 |
Why?
|
| Autopsy | 1 | 2018 | 995 | 0.030 |
Why?
|
| Longitudinal Studies | 2 | 2020 | 14124 | 0.030 |
Why?
|
| Signal Transduction | 1 | 2017 | 23154 | 0.030 |
Why?
|
| Young Adult | 1 | 2019 | 57163 | 0.030 |
Why?
|
| Fatal Outcome | 1 | 2018 | 1825 | 0.030 |
Why?
|
| Evidence-Based Medicine | 1 | 2024 | 3647 | 0.030 |
Why?
|
| Administration, Intranasal | 1 | 2012 | 472 | 0.020 |
Why?
|
| Vaccinia virus | 1 | 2012 | 334 | 0.020 |
Why?
|
| Lymphocyte Count | 1 | 2012 | 776 | 0.020 |
Why?
|
| Residence Characteristics | 1 | 2019 | 2004 | 0.020 |
Why?
|
| Animals | 3 | 2017 | 166558 | 0.020 |
Why?
|
| Health Surveys | 1 | 2019 | 3962 | 0.020 |
Why?
|
| Adult | 2 | 2019 | 215192 | 0.020 |
Why?
|
| Trachea | 1 | 2014 | 1082 | 0.020 |
Why?
|
| Particulate Matter | 1 | 2019 | 2518 | 0.020 |
Why?
|
| Th1 Cells | 1 | 2012 | 1005 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2024 | 21693 | 0.020 |
Why?
|
| United States | 2 | 2024 | 70437 | 0.020 |
Why?
|
| Time Factors | 2 | 2019 | 39622 | 0.010 |
Why?
|
| Interferon-gamma | 1 | 2012 | 3143 | 0.010 |
Why?
|
| Fibroblasts | 1 | 2012 | 4043 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2012 | 10138 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2019 | 38771 | 0.010 |
Why?
|
Concepts
(128)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(47)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_